Associated Papers
Clonal architecture of FLT3-ITD and acquired 13q uniparental disomy define prognostic heterogeneity and therapeutic vulnerabilities in acute myeloid leukemia.
Lai A et al.
Neoplasia (new York, N.y.), 2025
Myeloid sarcoma shows a high frequency of mutations activating the MAPK/ERK pathway and association with clonal hematopoiesis.
Nann D et al.
The Journal of Pathology. Clinical Research, 2025
Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia.
Zhao Y et al.
Annals of Hematology, 2024
Establishment and validation of a gene mutation-based risk model for predicting prognosis and therapy response in acute myeloid leukemia.
Liu Y et al.
Heliyon, 2024
FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
Seipel K et al.
Current Issues in Molecular Biology, 2024
CEBPA double mutations associated with ABO antigen weakness in hematologic diseases.
Choi SJ et al.
Blood Advances, 2024
Aging and comprehensive molecular profiling in acute myeloid leukemia.
Li JF et al.
Proceedings of the National Academy of Sciences of the United States of America, 2024
Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia.
Cheng WY et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
Acquired somatic variants in inherited myeloid malignancies.
Armes H et al.
Leukemia, 2022
Companion gene mutations and their clinical significance in AML with double mutant CEBPA.
Zhang Y et al.
Cancer Gene Therapy, 2020
CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations.
Su L et al.
Annals of Hematology, 2019
CEBPA mutational analysis in acute myeloid leukaemia by a laboratory-developed next-generation sequencing assay.
Ng CWS et al.
Journal of Clinical Pathology, 2018
Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significance.
Su L et al.
Oncotarget, 2018
CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.
Mannelli F et al.
Haematologica, 2017
Disease evolution and outcomes in familial AML with germline CEBPA mutations.
Tawana K et al.
Blood, 2015
A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.
Behdad A et al.
The Journal of Molecular Diagnostics : Jmd, 2015
Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
Wen XM et al.
International Journal of Clinical and Experimental Pathology, 2014
CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
Park SH et al.
Leukemia Research, 2013
Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models.
Kato N et al.
Blood, 2011
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
Ho PA et al.
Blood, 2009
Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation.
Renneville A et al.
Leukemia, 2009
AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples.
Shih LY et al.
Leukemia, 2006
Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations.
Fröhling S et al.
Genes, Chromosomes & Cancer, 2005